Research News
View articles by month and year
-
Heart Problems Caused by Herceptin May Be More Common Than Thought
A small study has found that after 3 months of Herceptin treatment nearly 58% of women had some loss of heart function.
-
Adding Avastin Slows Growth of Metastatic, HER2-Positive Disease
A study has found that adding Avastin (chemical name: bevacizumab) to a combination of Herceptin (chemical name: trastuzumab) and Taxotere (chemical name: docetaxel) increased the likelihood of respond...
-
Experimental Omnitarg May Help Treat Metastatic, HER2-Positive Disease
Research suggests that adding the experimental medicine Omnitarg to a combination of Herceptin and Taxotere slows the growth of metastatic HER2-positive breast cancer more than Herceptin and Taxotere alone.
-
Treating Early-Stage, HER2-Positive Disease with Herceptin and Chemo Combo with No Anthracycline Reduces Heart Risks
A study has found that Herceptin plus chemotherapy that didn't include an anthracycline after surgery was as effective as Herceptin plus chemotherapy that included an anthracycline for women diagnosed with HER2-positive, early-stage breast cancer.
-
Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission
Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible.
-
Tykerb Alone Doesn’t Work as Well as Herceptin Alone to Treat Early-Stage, HER2-Positive Disease
Early results from the ALTTO study show that Tykerb doesn't work as well as Herceptin when given alone after surgery to treat early-stage, HER2-positive breast cancer.
-
Older Women with Existing Heart Problems, Diabetes Have Higher Risk of Heart Function Problems with Herceptin
A small study suggests that women 70 and older who have existing heart problems or diabetes are more likely to develop heart problems if treated with Herceptin for breast cancer.
-
Adding Tykerb to Herceptin and Chemo Improves Survival in Metastatic, HER2-Positive Disease
Research suggests that treating women diagnosed with metastatic, HER2-positive breast cancer with Tykerb and Herceptin and chemotherapy improves survival compared to only Herceptin and chemotherapy.
-
Herceptin After Surgery Reduces Recurrence Risk of HER2-Positive, Early-Stage Disease
New research shows women diagnosed with early-stage, HER2-positive breast cancer who were treated with adjuvant chemotherapy then Herceptin for 1 year were 24% less likely to have the cancer come back compared to women who got adjuvant chemotherapy but no Herceptin.
-
Experimental Combo of Herceptin and Omnitarg Helps Treat Advanced-Stage HER2-Postitive Disease
Treatment before surgery with Herceptin and Omnitarg alone or with Taxotere benefited women diagnosed with locally-advanced or inflammatory HER2-positive breast cancer.
